Clinical Trials

T-cell Product Candidates

Product Candidate Phase Trial Number Trial Description
EBV-CTL 2 NCT01498484 Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From A Normal HLA- Compatible Or Partially- Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies
2 NCT00002663 Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies
Expanded
Access
NCT02822495 Study of Allogeneic EBV-CTLs in EBV-Associated Lymphomas and Lymphoproliferative Disorders
CMV-CTL 2 NCT02136797 Trial of Third Party Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation
2 NCT01646645 Primary Transplant Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation
WT1-CTL 1 NCT00620633 Dose Escalation Trial of WT1-Sensitized T Cells for Residual or Relapsed Leukemia After Allogeneic Hematopoietic Progenitor Cell Transplantation
1 NCT01758328 Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma
Molecularly Targeted Product Candidates
STM 434 1 NCT02262455 Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors